Unity Biotechnology Stock Analysis
| UBX Stock | USD 1.82 0.12 6.19% |
Unity Biotechnology is overvalued with Real Value of 1.51 and Target Price of 6.67. The main objective of Unity Biotechnology stock analysis is to determine its intrinsic value, which is an estimate of what Unity Biotechnology is worth, separate from its market price. There are two main types of Unity Biotechnology's stock analysis: fundamental analysis and technical analysis.
The Unity Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Unity Biotechnology is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Unity Stock trading window is adjusted to America/New York timezone.
Unity |
Unity Stock Analysis Notes
About 20.0% of the company outstanding shares are owned by institutional investors. The book value of Unity Biotechnology was at this time reported as 0.84. The company recorded a loss per share of 1.28. Unity Biotechnology had not issued any dividends in recent years. The entity had 1:10 split on the 20th of October 2022. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Unity Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. For more information please call Anirvan Ghosh at 650 416 1192 or visit https://unitybiotechnology.com.Unity Biotechnology Investment Alerts
| Unity Biotechnology is way too risky over 90 days horizon | |
| Unity Biotechnology may become a speculative penny stock | |
| Unity Biotechnology appears to be risky and price may revert if volatility continues | |
| Unity Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (39.86 M) with loss before taxes, overhead, and interest of (18.39 M). | |
| Unity Biotechnology has about 64.51 M in cash with (38.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Disposition of 642 shares by Anirvan Ghosh of Unity Biotechnology at 2.23 subject to Rule 16b-3 |
Unity Biotechnology Upcoming and Recent Events
Earnings reports are used by Unity Biotechnology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Unity Largest EPS Surprises
Earnings surprises can significantly impact Unity Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.48 | -0.34 | 0.14 | 29 | ||
2024-08-06 | 2024-06-30 | -0.46 | -0.31 | 0.15 | 32 | ||
2022-11-08 | 2022-09-30 | -1.65 | -1.36 | 0.29 | 17 |
Unity Stock Institutional Investors
| Shares | Cercano Management Llc | 2024-12-31 | 41.2 K | State Street Corp | 2024-12-31 | 37.8 K | Commonwealth Equity Services Inc | 2024-12-31 | 24.2 K | Northern Trust Corp | 2024-12-31 | 22.5 K | Jane Street Group Llc | 2024-12-31 | 21.2 K | Susquehanna International Group, Llp | 2024-12-31 | 18.7 K | Squarepoint Ops Llc | 2024-12-31 | 18.3 K | Endowment Wealth Management, Inc. | 2024-12-31 | 12.5 K | Advisor Group Holdings, Inc. | 2024-12-31 | 11.3 K | Arch Venture Corp | 2024-12-31 | 1 M | Alyeska Investment Group, L.p. | 2024-12-31 | 859.1 K |
Unity Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 27.8 M.Unity Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.70) | (0.73) | |
| Return On Capital Employed | (0.89) | (0.93) | |
| Return On Assets | (0.70) | (0.73) | |
| Return On Equity | (1.61) | (1.53) |
Management Efficiency
Unity Biotechnology has Return on Asset of (0.3034) % which means that on every $100 spent on assets, it lost $0.3034. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.8695) %, meaning that it generated no profit with money invested by stockholders. Unity Biotechnology's management efficiency ratios could be used to measure how well Unity Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2025. Return On Capital Employed is likely to drop to -0.93 in 2025. At this time, Unity Biotechnology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 25.2 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 57.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.21 | 2.10 | |
| Tangible Book Value Per Share | 2.21 | 2.10 | |
| Enterprise Value Over EBITDA | (1.10) | (1.16) | |
| Price Book Value Ratio | 0.90 | 1.07 | |
| Enterprise Value Multiple | (1.10) | (1.16) | |
| Price Fair Value | 0.90 | 1.07 | |
| Enterprise Value | 69.7 M | 66.2 M |
Unity Biotechnology's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 26th of February, Unity Biotechnology has the Coefficient Of Variation of 916.61, semi deviation of 5.43, and Risk Adjusted Performance of 0.0894. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unity Biotechnology, as well as the relationship between them.Unity Biotechnology Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Unity Biotechnology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Unity Biotechnology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Unity Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unity Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unity Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unity Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unity Biotechnology Outstanding Bonds
Unity Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unity Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unity bonds can be classified according to their maturity, which is the date when Unity Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Unity Biotechnology Predictive Daily Indicators
Unity Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Unity Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Unity Biotechnology Forecast Models
Unity Biotechnology's time-series forecasting models are one of many Unity Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Unity Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Unity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Unity Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Unity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Unity Biotechnology. By using and applying Unity Stock analysis, traders can create a robust methodology for identifying Unity entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (292.02) | (277.42) | |
| Operating Profit Margin | (280.54) | (266.51) | |
| Net Loss | (281.39) | (267.32) | |
| Gross Profit Margin | (7.41) | (7.78) |
Current Unity Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Unity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Unity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 6.67 | Strong Buy | 2 | Odds |
Most Unity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Unity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Unity Biotechnology, talking to its executives and customers, or listening to Unity conference calls.
Unity Stock Analysis Indicators
Unity Biotechnology stock analysis indicators help investors evaluate how Unity Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Unity Biotechnology shares will generate the highest return on investment. By understating and applying Unity Biotechnology stock analysis, traders can identify Unity Biotechnology position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 13.6 M | |
| Common Stock Shares Outstanding | 14.8 M | |
| Total Stockholder Equity | 28.4 M | |
| Property Plant And Equipment Net | 18.1 M | |
| Cash And Short Term Investments | 43.2 M | |
| Cash | 19.8 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | 7.2 M | |
| 50 Day M A | 1.684 | |
| Total Current Liabilities | 7.8 M | |
| Other Operating Expenses | 44.7 M | |
| Non Current Assets Total | 19.1 M | |
| Non Currrent Assets Other | 1 M | |
| Stock Based Compensation | 7.4 M |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.